Ophthalmology

Diorasis, Northway Biotech team up on glaucoma gene therapy development

Diorasis Therapeutics (DTx’s), a preclinical-stage biotechnology firm specialising in gene therapies for ophthalmic conditions, has joined forces with Northway Biotech (NBT), a contract development and manufacturing organisation (CDMO).

FDA grants fast track designation to Sanofi’s SAR446597

The US Food and Drug Administration (FDA) has granted fast track designation to SAR446597, a new intravitreal gene therapy designed as a one-time treatment for geographic atrophy (GA) due to age-related macular degeneration (AMD).

Golden Age Health secures rights to promote LX-101 gene therapy in China

Golden Age Health (GAH) has secured exclusive rights to commercialise and promote Innostellar Biotherapeutics' first-in-class gene therapy candidate, LX-101, in mainland China.

Formycon, Bio Usawa to introduce ophthalmic medicine in Sub-Saharan Africa

Formycon has announced that Bioeq, the exclusive licencee for FYB201, has partnered with Bio Usawa Biotechnology to introduce the ophthalmic medicine in Sub-Saharan Africa.

US FDA approves Alcon’s Tryptyr ophthalmic solution for Dry Eye Disease

Alcon has received the US Food and Drug Administration (FDA) approval for its Tryptyr (acoltremon ophthalmic solution) 0.003% for the treatment of signs and symptoms of Dry Eye Disease (DED).

Perceive Pharma secures $15m to advance neuroprotective therapeutic development

Perceive Pharma has secured $15m in a Series A funding round to expedite neuroprotective therapeutic development in glaucoma and other indications.

Ring Therapeutics signs partnerships to advance R&D in biomedical sciences

Ring Therapeutics has entered into new strategic partnerships with the Agency for Science, Technology, and Research (A*STAR) and the Singapore Eye Research Institute (SERI) to enhance research and development (R&D) efforts in the biomedical sciences sector.

Amgen’s TEPEZZA gets Japan’s MHLW approval for thyroid eye disease treatment

Amgen has announced the receipt of approval from the Japan’s Ministry of Health, Labour and Welfare (MHLW) for TEPEZZA (Teprotumumab) to treat active or high clinical activity score (CAS) thyroid eye disease (TED).

Skyline Therapeutics secures FDA orphan drug status for RP therapy

Skyline Therapeutics has announced that the US Food and Drug Administration (FDA) granted orphan drug designation (ODD) to its gene therapy, SKG1108, for the treatment of Retinitis Pigmentosa (RP), an inherited retinal disease.